Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 05, 2020 07:00 ET | Source: ProQR Therapeutics N.V.

ProQR Appoints Naveed Shams, MD, PhD as Chief Scientific Officer

LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
September 24, 2020 16:10 ET | Source: ProQR Therapeutics N.V.

ProQR Announces Virtual Presentations at Scientific Conferences

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
September 03, 2020 07:00 ET | Source: ProQR Therapeutics N.V.

ProQR to Participate in Upcoming Investor Conferences

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
August 06, 2020 16:30 ET | Source: ProQR Therapeutics N.V.

ProQR Announces Second Quarter 2020 Operating and Financial Results

Positive preliminary data from InSight extension study of sepofarsen for LCA10 reported – consistent with benefit seen in Phase 1/2 and building confidence in Phase 2/3 Illuminate trial;Strategic...
July 21, 2020 07:00 ET | Source: ProQR Therapeutics N.V.

ProQR Strengthens Scientific Advisory Board with Leaders in Inherited Retinal Disease and RNA Therapy

LEIDEN, Netherlands & CAMBRIDGE, Mass., July 21, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
July 14, 2020 16:30 ET | Source: ProQR Therapeutics N.V.

ProQR Announces $30 Million Strategic Convertible Debt Financing Agreement with Pontifax Ventures

Extends ProQR’s cash runway into 2023ProQR can trigger conversion of the debt to equity at $7.88 per share, under certain conditions LEIDEN, Netherlands & CAMBRIDGE, Mass. , July 14, 2020 ...
July 13, 2020 16:30 ET | Source: ProQR Therapeutics N.V.

ProQR Announces Expert Perspectives Call on LCA10 and Sepofarsen

LEIDEN, Netherlands & CAMBRIDGE, Mass., July 13, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
June 12, 2020 07:00 ET | Source: ProQR Therapeutics N.V.

ProQR Announces Expert Perspectives Conference Call Series

LEIDEN, Netherlands & CAMBRIDGE, Mass., June 12, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
June 08, 2020 07:00 ET | Source: ProQR Therapeutics N.V.

ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Data Through the Association for Research in Vision and Ophthalmology (ARVO)

LEIDEN, Netherlands & CAMBRIDGE, Mass., June 08, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
May 25, 2020 07:00 ET | Source: ProQR Therapeutics N.V.

ProQR Announces Annual Meeting of Shareholders

Leiden, Netherlands & Cambridge, Mass., May 25, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...